TOKYO, June 29, 2026
Eisai Co., Ltd. has announced it will present more than 50 scientific presentations highlighting the latest advances in its Alzheimer’s disease (AD) research portfolio during the Alzheimer’s Association International Conference (AAIC) 2026, taking place from July 12–15 in London and online. The company’s comprehensive scientific program includes 52 research abstracts covering its lead anti-amyloid therapy LEQEMBI® (lecanemab), investigational subcutaneous formulations, real-world clinical evidence, blood-based biomarkers, and next-generation tau-targeting antibody etalanetug (E2814). The presentations reinforce Eisai’s commitment to advancing disease-modifying therapies for Alzheimer’s disease, focusing on earlier diagnosis, long-term treatment strategies, patient-centered care, and innovative therapeutic approaches designed to slow disease progression. The broad scientific portfolio also demonstrates the company’s continued leadership in neurological research while expanding understanding of treatment effectiveness in both controlled clinical trials and real-world healthcare settings.
LEQEMBI Research Highlights Real-World Evidence and Long-Term Care
A major focus of Eisai’s AAIC 2026 program will be LEQEMBI (lecanemab), the company’s anti-amyloid beta protofibril monoclonal antibody developed for the treatment of early Alzheimer’s disease. Scientific sessions will feature new evidence evaluating subcutaneous administration, maintenance dosing strategies, patient experiences, physician satisfaction, and long-term treatment outcomes across diverse clinical settings. One of the conference highlights will be findings from the LEADER Study, a comprehensive multicenter real-world analysis examining three years of clinical experience following LEQEMBI approval.
Researchers will present data on monthly maintenance dosing, at-home subcutaneous administration, treatment outcomes across different patient populations, and healthcare provider experiences. Additional presentations will explore post-marketing safety observations, biomarker changes following treatment, racial and ethnic differences in clinical outcomes, and real-world adoption patterns, providing clinicians with valuable evidence supporting the evolving use of anti-amyloid therapies in routine neurological practice.
Pipeline Innovation Expands Alzheimer’s Disease Research
Advertisement
Beyond LEQEMBI, Eisai will present important updates from several investigational Alzheimer’s disease programs designed to address multiple biological pathways involved in disease progression. New findings from the Phase 3 AHEAD 3-45 clinical trial will provide updates on participant retention and progress in individuals with preclinical Alzheimer’s disease, while additional presentations will evaluate etalanetug (E2814), an investigational anti-MTBR tau monoclonal antibody being studied in combination with lecanemab. Researchers will also present new data on blood-based biomarkers, digital cognitive assessments, diagnostic pathways, proteomics, healthcare economics, and patient quality-of-life outcomes, reflecting Eisai’s comprehensive strategy to improve both diagnosis and long-term disease management. The conference program further includes an Eisai-sponsored symposium on early intervention in Alzheimer’s disease, emphasizing the growing importance of initiating treatment before significant neurological decline occurs.
By combining advances in anti-amyloid therapy, tau-targeted biologics, precision biomarkers, and real-world clinical evidence, Eisai continues to strengthen its leadership in Alzheimer’s disease research and therapeutic innovation. The extensive scientific presentations at AAIC 2026 demonstrate the company’s long-term commitment to developing disease-modifying therapies that may improve patient outcomes, support earlier intervention, enhance treatment accessibility through innovative delivery methods, and expand scientific understanding of one of the world’s most challenging neurodegenerative disorders. As Alzheimer’s disease continues to affect millions of individuals globally, Eisai’s expanding research portfolio reflects ongoing progress toward more personalized, durable, and effective therapeutic strategies capable of transforming the future of dementia care.
Source: Eisai press release
